Picture [iito] No Tracking 650x80px
Document › Details

AB-Biotics S.A.. (10/28/13). "Press Release: AB-Biotics Acquires a Patent for Predicting Antipsychotic-induced Extrapyramidal Symptoms". Barcelona.

Organisations Organisation AB-Biotics S.A.
  Organisation 2 University of Barcelona
Products Product clinical genomic test (nucleic acid diagnostics)
  Product 2 Neurofarmagen genetic test (product series)
Person Person Peláez, Nuria (AB-Biotics 201310 Chief Communications Officer)

> This DNA-based method can predict the risk of a patient treated with antipsychotic drugs developing side effects affecting movement, such as parkinsonism

> The method will be incorporated into Neurofarmagen, a genetic test which helps doctors identify the most appropriate treatment for each neuropsychiatric patient

The Spanish biotech company AB-Biotics, traded on the Spanish Alternative Stock Market (MAB), has acquired the rights to a patent which allows to predict the high or low risk of a patient treated with antipsychotic drugs developing extrapyramidal symptoms. This type of side effects induced by antipsychotic drugs affect patient movement and include muscle rigidity, parkinsonism, akinesia (inability to initiate movement) and akathisia (inability to remain motionless), among others. This information helps doctors identify the most appropriate treatment for each patient, since the side effects are a major cause of abandonment of such treatments.

This technology will be incorporated into Neurofarmagen, a genetic test developed by AB-Biotics which identifies most optimum medication for each individual patient with depression, schizophrenia, bipolar disorder or epilepsy by analyzing their DNA, extracted from a sample of saliva. Neurofarmagen is currently marketed in Spain, through Almirall; in Brazil, through GlaxoSmithKline, and Mexico, through Scienta Farma.

The patent was developed by University of Barcelona (UB), Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona and Consorcio Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM).

About AB-Biotics

AB-Biotics is a biotechnology company focused on research, development, protection and distribution of biotech unique solutions to improve the health and wellbeing of people. Its areas of activity include the development of pharmacogenetic tests for neuropsychiatry, and probiotics and other functional ingredients for the food and pharmaceutical industries. AB-Biotics is listed on the Spanish Alternative Investment Market (MAB). The company began in 2012 its international expansion and has closed several agreements for marketing their products in America, Europe and Asia.

Press contact:
Nuria Peláez - Chief Communications Officer

Record changed: 2016-01-10


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for AB-Biotics S.A.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top